NCT04880213View on ClinicalTrials.gov

Study of M5049 in Healthy Japanese and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

November 23, 2021

Study Completion Date

November 23, 2021

Conditions
Healthy
Interventions
DRUG

M5049

Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.

DRUG

M5049

Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.

DRUG

M5049

Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.

Trial Locations (1)

Unknown

Covance Clinical Research Unit Ltd., Leeds

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY